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FOETAL ANTIGENS - CURRENT
CLINICAL APPLICATIONS. A. MUNRO
NEVILLE. Division of Pathology, Chester
Beatty Research Institute, London.
For many years past, the energies of many
scientists have been devoted to attempting to
evolve a test, or series of tests, with universal
application to facilitating the diagnosis not
only of primary but also of metastatic
tumours. Many have been proposed; none
has yet proved satisfactory.
The recent evidence that human tumours
express distinct neoantigens has provided a
new approach to the problem. The onco-
foetal antigens represent one class of tumour
associated antigens which are released by the
tumours into the body fluids. Many have
now been described, of which the carcino-
embryonic antigen (CEA) and alpha-foeto-
protein (AFP) have been studied in greatest
detail.
Raised levels of plasma CEA or CEA-like
material occur with a wide variety of tumours
of different histogenesis. The mass of
tumours and their extent of spread are
important in determining the plasma levels.
Inflammatory conditions also raise their
levels. Hence, it would seem to have little
value in assisting with the earlier or differ-
ential diagnosis of malignancy. Recent
evidence tends to suggest that the prognosis
of a particular tumour may be related to the
pre-operative CEA levels. Moreover, rises in
plasma CEA may antedate by 3-18 months
the clinical detection of recurrent or metasta-
tic colorectal tumours.
CEA or CEA-like materials also occur in
biological fluids other than plasma and their
diagnostic role in such sites remains to be
examined with the exception of urine and
urothelial carcinoma.
Elevated plasma levels of AFP were
originally considered to be specific for
hepatocellular carcinoma and malignant tera-
tomata of gonadal and extra-gonadal origin.
With the development of sensitive radio-
immunoassays, other tumours including
gastrointestinal and prostatic carcinomata
and non-neoplastic hepatic disease, may yield
plasma levels which overlap with those found
in primary liver cancer. Moreover, raised
AFP levels have not been found in the pre-
clinical phase of this tumour.
Thus, like CEA, AFP seems to offer little
in the diagnostic phase. Its principal role
seems to be as an index of recurrent or
metastatic disease.
CLINICAL AND TECHNICAL EVALUA-
TION OF THE MOD-NEM TEST FOR
MALIGNANT DISEASE. J. A. V.
PRITCHARD, J. L. MOORE, W. H. SUTHER-
LAND and C. A. F. JOSLIN. Tenovus
Laboratories, Velindre Hospital, Whitchurch,
Cardiff.
Field and Caspary (Lancet, 1970, ii, 1337;
Br. med. J., 1971, ii, 613) reported that
peripheral lymphocytes from patients with
malignant disease were sensitized to a basic
protein (EF) derived from human brain.
Sensitized lymphocytes in contact with EF
produce a substance (macrophage slowing
factor, MSF) capable of reducing the electro-
phoretic mobility of guinea-pig macrophages.
The slowing of macrophages was shown to be
related to the host malignant condition and
a nonspecific test, the macrophage electro-
phoretic mobility (MEM) test for cancer was
proposed. This was confirmed by Pritchard
et al. (Lancet, 1972, ii, 627). The MEM test
in its original form was technically difficult
to operate for two main reasons: (a) the
equipment available to measure the electro-
phoretic mobility of macrophages was prone
to many technical faults and (b) the selection
of slowed macrophages within the macro-
phage population required considerable
training. In order that the MEM test could
become more acceptable in general laboratory